PLCB2 and breast carcinoma: Given that, unlike other breast cancer subtypes, effective targeted therapy is not currently available for TNBC tumors and considering that the selective removal of BCSCs cells may have a great clinical importance, our results indicate that up-modulation of PLC-β2 is a promising tool for novel therapies aimed to prevent the progression of aggressive breast tumors.